

REMARKS

In response to the Notice of Non-Responsive Reply, Applicants hereby elect Cyclo[N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe], i.e. the second compound of Claim 8 for examination as a first priority. As a second priority, Applicants elect D-Phe-[Cys-Phe-D-Try-Lys-Thr-Cys]Thr-ol, i.e. the compound of claim 9.

As proscribed by 37 CFR §1.821, Applicant hereby submits a Second Supplemental Sequence Listing, in both computer readable and paper form. Additionally, Applicant submits the required statement under 37 CFR §1.821(f).

As described under 37 CFR §1.821(a)(2) and MPEP §2422.02, only those amino acid sequences without D-amino acids are subject to the sequence listing rules. Therefore, only those amino acid sequences subject to 37 CFR §1.821 are contained in the attached Supplemental Sequence Listing.

Respectfully submitted,



Thomas P. Pavelko  
Registration No. 31,689

TPP/EPR/mat  
Attorney Docket No.: TPP 30566

STEVENS, DAVIS, MILLER & MOSHER, L.L.P.  
1615 L Street, N.W., Suite 850  
Washington, D.C. 20036  
Telephone: (202) 785-0100  
Facsimile: (202) 408-5200 or (202) 408-5088

Date: Sept 21, 2001